Search

Your search keyword '"Riazalhosseini, Yasser"' showing total 309 results

Search Constraints

Start Over You searched for: Author "Riazalhosseini, Yasser" Remove constraint Author: "Riazalhosseini, Yasser"
309 results on '"Riazalhosseini, Yasser"'

Search Results

2. Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer

6. PD16-03 UNDERSTANDING THE MOLECULAR CHARACTERISTICS AND VULNERABILITIES OF SARCOMATOID/RHABDOID RENAL CELL CARCINOMAS THROUGH INTEGRATIVE HISTOLOGICAL AND SPATIAL GENOMICS APPROACHES

8. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles

9. Morphological findings in frozen non-neoplastic kidney tissues of patients with kidney cancer from large-scale multicentric studies on renal cancer

10. Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.

11. Contribution of genetic variants in the development of familial premature coronary artery disease in a cohort of cardiac patients.

14. Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion

15. Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer

16. Abstract B011: An atlas of cellular heterogeneity in primary and metastatic renal cell carcinomas

19. Abstract PR005: An atlas of cellular heterogeneity in primary and metastatic renal cell carcinomas

20. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer

21. Latency and interval therapy affect the evolution in metastatic colorectal cancer

22. P292: Contribution of rare variants in the development of familial premature coronary artery disease in a cohort of cardiac patients

24. Abstract 69: Minimally invasive brain metastases are characterized by elevated immune cell infiltrate

25. Supplementary Methods S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

26. Figure S3 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

27. Supplementary Tables S3-S13 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

28. Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

29. Data from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

30. Supplementary Figure 10 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

31. Supplementary Figure 4 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

32. Supplementary Figure 5 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

33. Supplementary Figure 2 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

34. Supplementary Table 2 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

35. Supplementary Figure 7 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

36. Supplemental Data from Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer

37. Supplementary Figure 9 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

38. Supplementary Figure 8 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

39. Conflict of Interest Patent Info from Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer

40. Supplementary Table 3 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

41. Supplementary Figure 3 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

42. Supplementary Table 1 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

43. Supplementary Figure 6 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

44. Supplementary Table 3 from Epigenetically Deregulated microRNA-375 Is Involved in a Positive Feedback Loop with Estrogen Receptor α in Breast Cancer Cells

45. Supplementary Methods, Figures 1-2, Tables 1-2 from Epigenetically Deregulated microRNA-375 Is Involved in a Positive Feedback Loop with Estrogen Receptor α in Breast Cancer Cells

46. Data from Epigenetically Deregulated microRNA-375 Is Involved in a Positive Feedback Loop with Estrogen Receptor α in Breast Cancer Cells

47. Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

49. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

50. Combined burden and functional impact tests for cancer driver discovery using DriverPower

Catalog

Books, media, physical & digital resources